Dr. John Cush RheumNow
3 years 9 months ago
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with SLE were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to data.
https://t.co/mRUOVrKbt2 https://t.co/m18DWxSV20
Dr. John Cush RheumNow
3 years 9 months ago
Retrospective study of US National Inpatient Sample data 2015-2019 looked at 60,360 gout admissions, roughly 1/4 had Arrhythmias (mostly older pts; AFib (88%), atr flutter (6.2%), VTach (3.2%). Gout-arrhythmia pts had more deaths (adj OR 2.06) https://t.co/L1WEsybI7h https://t.co/xwAfFVJOuk
Dr. John Cush RheumNow
3 years 9 months ago
In pts undergoing hip or knee arthroplasty for OA, aspirin (3.45%) compared with enoxaparin (1.82%) resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism https://t.co/7hgLbynNx6 https://t.co/HMc4UbMcdy
Dr. John Cush RheumNow
3 years 9 months ago
RA-ILD takes centre stage
Greg McDermott presented abstract 2248 on the prevalence and mortality of subpleural interstitial lung abnormalities (ILA) in RA and non-RA comparators.
https://t.co/zrg7IEhBfg https://t.co/dKACCzr4CZ
Dr. John Cush RheumNow
3 years 9 months ago
More Than a Conference:Life’s Lessons
By: @KDAO2011
This is my 20th year attending the ACR meeting; despite my virtual attendance, I was still able to connect w/people. I reflected on my experiences w/ the conference and wanted to share my life lessons.
https… https://t.co/9gBbaYBujc
A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow biosimilars to enter the market sooner and could also lower health care costs with improved access.
Dr. John Cush RheumNow
3 years 9 months ago
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Dr. John Cush RheumNow
3 years 9 months ago
Sleep Quality & PsA
Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c
Dr. John Cush RheumNow
3 years 9 months ago
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie
Dr. John Cush RheumNow
3 years 9 months ago
Methotrexate + pegloticase increases response rates in gout
Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents.
https://t.co/8cqsAXuzIB https://t.co/OSpf5ehiCm
Dr. John Cush RheumNow
3 years 9 months ago
Best of ACR Day Two in PSA
https://t.co/FXGCPaTGX6 https://t.co/WICtjVICC2
Dr. John Cush RheumNow
3 years 9 months ago
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash ( @drpnash) discusses Abstract 1018 at #ACR22 Convergence.
https://t.co/Wk3ibuh9ip https://t.co/FcLjDMJCgr
Dr. John Cush RheumNow
3 years 9 months ago
Low-grade Proteinuria in Non Renal Lupus: Should We be Worried?
Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22
https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2
